Suppr超能文献

一名身材矮小且近期可能感染新型冠状病毒的儿童发生垂体卒中。

Pituitary Apoplexy in a Child with Short Stature and Possible Recent SARS-CoV-2 Infection.

作者信息

Barbu Carmen Gabriela, Cima Luminita Nicoleta, Andrei Marian, Vasilache Simona, Țarnă Mihaela, Rizea Ileana Olguta, Martin Carmen Sorina, Sîrbu Anca Elena, Fica Simona

机构信息

Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, Carol Davila University of Medicine and Pharmacy, 020021 Bucharest, Romania.

Department of Endocrinology, Diabetes Mellitus, Nutrition and Metabolic Disorders, Elias Emergency University Hospital, 011461 Bucharest, Romania.

出版信息

Diagnostics (Basel). 2025 Jun 7;15(12):1453. doi: 10.3390/diagnostics15121453.

Abstract

Pituitary apoplexy is an extremely rare condition in children and adolescents with a rapid onset due to acute hemorrhage, infarction, or both in the pituitary gland. Most frequently, pituitary apoplexy is an asymptomatic or subclinical entity. Few cases of pituitary apoplexy with concurrent SARS-CoV-2 infection or COVID-19 vaccination have been reported. We present the case of a 13-year-8-month-old boy who presented in our pediatric endocrinology department for the evaluation of short stature. He was previously diagnosed with secondary hypothyroidism and was treated with levothyroxine. At admission, clinical examination revealed a height of 141 cm (-2.68 SD/-2.4 SD corrected for mid-parental height), normal weight (60th centile), Tanner-stage G2P1, and delayed bone age. Basal IGF1 was normal, but the tests performed to assess the GH reserve confirmed the GH deficiency (peak GH value 3.11 ng/mL after clonidine/0.95 ng/mL after insulin). The brain MRI revealed a subacute pituitary hemorrhage. Thrombophilia and coagulopathies were excluded by further testing. Anti-SARS-CoV-2 (anti-S-protein IgG) antibodies (>200 BAU/mL) were compatible with COVID-19 infection, indicating a possible association between these two entities. At 3-month follow-up, physical examination showed a 3 cm height gain and advancing pubertal development (G4P2). Newer MRI found changes consistent with resolving hemorrhage. The patient was provided immediately with recombinant human GH and aromatase inhibitor therapy to maximize GH treatment response. During follow-up, the rGH dose was adjusted based on IGF1 values, and after 3 years and 10 months, rGH treatment was stopped, reaching a height of 172.3 cm (-0.51 SD) and surpassing the initial prediction of 164.5 cm. Pituitary apoplexy, an even rarer complication in the pediatric population, may be associated with SARS-CoV-2 infection. Further studies are necessary to better understand the intertwining of those conditions.

摘要

垂体卒中在儿童和青少年中是一种极其罕见的病症,起病迅速,是由于垂体急性出血、梗死或两者兼而有之所致。垂体卒中最常见的情况是无症状或亚临床状态。很少有关于垂体卒中合并严重急性呼吸综合征冠状病毒2(SARS-CoV-2)感染或2019冠状病毒病(COVID-19)疫苗接种的病例报道。我们报告了一例13岁8个月大的男孩,他因身材矮小到我们儿科内分泌科就诊。他之前被诊断为继发性甲状腺功能减退,并接受左甲状腺素治疗。入院时,临床检查显示身高141厘米(标准差-2.68 /根据父母平均身高校正后的标准差-2.4),体重正常(第60百分位),坦纳分期G2P1,骨龄延迟。基础胰岛素样生长因子1(IGF1)正常,但评估生长激素(GH)储备的检查证实存在GH缺乏(可乐定后GH峰值3.11纳克/毫升/胰岛素后0.95纳克/毫升)。脑部磁共振成像(MRI)显示亚急性垂体出血。通过进一步检查排除了血栓形成倾向和凝血障碍。抗SARS-CoV-2(抗S蛋白IgG)抗体(>200 BAU/毫升)与COVID-19感染相符,表明这两种情况之间可能存在关联。在3个月的随访中,体格检查显示身高增加了3厘米,青春期发育进展(G4P2)。新的MRI检查发现了与出血吸收相符的变化。立即为患者提供重组人生长激素和芳香化酶抑制剂治疗,以最大限度地提高生长激素治疗反应。在随访期间,根据IGF1值调整重组人生长激素剂量,3年10个月后,停止重组人生长激素治疗,身高达到172.3厘米(标准差-0.51),超过了最初预测的164.5厘米。垂体卒中在儿科人群中是一种更为罕见的并发症,可能与SARS-CoV-2感染有关。需要进一步研究以更好地理解这些情况之间的相互关系。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/90db/12192251/7e7aefde92fa/diagnostics-15-01453-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验